Rational design and engineering of therapeutic proteins.

[1]  J. Young,et al.  Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. , 1988, The Journal of biological chemistry.

[2]  B. Matthews,et al.  Design and structural analysis of alternative hydrophobic core packing arrangements in bacteriophage T4 lysozyme. , 1993, Journal of molecular biology.

[3]  D. Goeddel,et al.  Rational design of potent antagonists to the human growth hormone receptor. , 1992, Science.

[4]  T. Arakawa,et al.  Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed , 1993, Journal of protein chemistry.

[5]  F M Richards,et al.  Optimal sequence selection in proteins of known structure by simulated evolution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Ciliberto,et al.  Rational design of a receptor super‐antagonist of human interleukin‐6. , 1994, The EMBO journal.

[7]  J R Desjarlais,et al.  De novo design of the hydrophobic cores of proteins , 1995, Protein science : a publication of the Protein Society.

[8]  D A Lauffenburger,et al.  Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.

[9]  V. Mukku,et al.  Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol* , 1996, The Journal of Biological Chemistry.

[10]  P. Bjorkman,et al.  Fc receptors and their interactions with immunoglobulins. , 1996, Annual review of cell and developmental biology.

[11]  S. L. Mayo,et al.  Protein design automation , 1996, Protein science : a publication of the Protein Society.

[12]  L. Presta,et al.  Antibody Humanization Using Monovalent Phage Display* , 1997, The Journal of Biological Chemistry.

[13]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[14]  Raimund J. Ober,et al.  Increasing the serum persistence of an IgG fragment by random mutagenesis , 1997, Nature Biotechnology.

[15]  S. L. Mayo,et al.  De novo protein design: fully automated sequence selection. , 1997, Science.

[16]  R. Kaufman,et al.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. L. Mayo,et al.  Automated design of the surface positions of protein helices , 1997, Protein science : a publication of the Protein Society.

[18]  W. Sheffield,et al.  Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. , 1997, Blood.

[19]  C. Barbas,et al.  A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Griffiths,et al.  Strategies for selection of antibodies by phage display. , 1998, Current opinion in biotechnology.

[21]  Stephen L. Mayo,et al.  Design, structure and stability of a hyperthermophilic protein variant , 1998, Nature Structural Biology.

[22]  B. Weintraub,et al.  A rational design strategy for protein hormone superagonists , 1998, Nature Biotechnology.

[23]  G. Martiny-Baron,et al.  An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Vessella,et al.  Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. , 1998, Immunotechnology : an international journal of immunological engineering.

[25]  I. Macdougall,et al.  Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[26]  Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD. , 1999, Protein engineering.

[27]  B. Weintraub,et al.  Development and in vitro characterization of human recombinant thyrotropin. , 1999, Thyroid : official journal of the American Thyroid Association.

[28]  G. Antonelli,et al.  Development of antibodies to interferon beta in patients: technical and biological aspects. , 1999, European cytokine network.

[29]  S. L. Mayo,et al.  Computational protein design. , 1999, Structure.

[30]  A. D. de Vos,et al.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.

[31]  Jin‐Kyoo Kim,et al.  Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn , 1999, European journal of immunology.

[32]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[33]  P. Shaw,et al.  Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. , 1999, Life sciences.

[34]  A. Sytkowski,et al.  An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties* , 1999, The Journal of Biological Chemistry.

[35]  M. Goldenberg,et al.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. , 1999, Clinical therapeutics.

[36]  D. Collen,et al.  Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. , 2000, Blood.

[37]  Junichi Takagi,et al.  Computational design of an integrin I domain stabilized in the open high affinity conformation , 2000, Nature Structural Biology.

[38]  M. Blaber,et al.  Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life. , 2000, Biochemistry.

[39]  W. Duckworth,et al.  Genetically engineered insulin analogs: diabetes in the new millenium. , 2000, Pharmacological reviews.

[40]  E. Padlan,et al.  Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only , 2000, The Journal of Immunology.

[41]  J R Desjarlais,et al.  Computational protein design. , 2001, Current opinion in chemical biology.

[42]  A. Plückthun,et al.  Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.

[43]  J. V. Ravetch,et al.  IgG Fc receptors. , 2001, Annual review of immunology.

[44]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[45]  V. Bhakta,et al.  A Barbourin-albumin Fusion Protein that Is Slowly Cleared In Vivo Retains the Ability to Inhibit Platelet Aggregation In Vitro , 2001, Thrombosis and Haemostasis.

[46]  Christopher A. Voigt,et al.  Computationally focusing the directed evolution of proteins , 2001, Journal of cellular biochemistry. Supplement.

[47]  T M Handel,et al.  Review: protein design--where we were, where we are, where we're going. , 2001, Journal of structural biology.

[48]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[49]  Timothy A. Springer,et al.  Reversibly locking a protein fold in an active conformation with a disulfide bond: Integrin αL I domains with high affinity and antagonist activity in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Shimaoka,et al.  An isolated, surface-expressed I domain of the integrin αLβ2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Damon L. Meyer,et al.  Reduced antibody response to streptavidin through site‐directed mutagenesis , 2001, Protein science : a publication of the Protein Society.

[52]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[53]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[54]  Raphael Guerois,et al.  Energy estimation in protein design. , 2002, Current opinion in structural biology.

[55]  Anirban Kundu,et al.  Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening , 2002, Protein science : a publication of the Protein Society.

[56]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[57]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[58]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[59]  Anirban Kundu,et al.  Computational stabilization of human growth hormone , 2002, Protein science : a publication of the Protein Society.

[60]  S. A. Marshall,et al.  Electrostatics significantly affect the stability of designed homeodomain variants. , 2002, Journal of molecular biology.

[61]  Christopher A. Voigt,et al.  Protein building blocks preserved by recombination , 2002, Nature Structural Biology.

[62]  Min Zhang,et al.  Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.

[63]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.